- $306.18m
- $151.70m
- $38.63m
- 69
- 24
- 65
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.48 | ||
| Price to Tang. Book | 1.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.89% | ||
| Return on Equity | -18.73% | ||
| Operating Margin | -132.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.17 | 33.89 | 44.26 | 41.29 | 38.63 | 41.3 | 49.55 | 12.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Directors
- Richard Douglas NEC (68)
- Douglas Doerfler PRE (65)
- Amanda Murphy CFO (44)
- Maher Masoud EVP (46)
- Thomas Ross EVP (60)
- Ronald Holtz SVP (63)
- James Brady VPR
- Kevin Gutshall VPR
- Steve Nardi VPR (58)
- Kathryn Wekselman VPR
- Sarah Meeks VBD
- Yasir Al-Wakeel NED (39)
- Rekha Hemrajani NED (52)
- William Brooke NID (65)
- Stanley Erck NID (73)
- John Johnston NID (62)
- Arthur Mandell NID (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 31st, 1998
- Public Since
- March 29th, 2016
- No. of Shareholders
- 29
- No. of Employees
- 114
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 106,313,718
- Address
- 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, 20850
- Web
- https://www.maxcyte.com/
- Phone
- +1 3015175556
- Auditors
- CohnReznick LLP
Latest News for MXCT
Upcoming Events for MXCT
Q1 2025 MaxCyte Inc Earnings Release
Q1 2025 MaxCyte Inc Earnings Call
MaxCyte Inc Annual Shareholders Meeting
MaxCyte Inc Annual Shareholders Meeting
Similar to MXCT
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 21:57 UTC, shares in MaxCyte are trading at $2.88. This share price information is delayed by 15 minutes.
Shares in MaxCyte last closed at $2.88 and the price had moved by -21.95% over the past 365 days. In terms of relative price strength the MaxCyte share price has underperformed the S&P500 Index by -27.96% over the past year.
The overall consensus recommendation for MaxCyte is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMaxCyte does not currently pay a dividend.
MaxCyte does not currently pay a dividend.
MaxCyte does not currently pay a dividend.
To buy shares in MaxCyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.88, shares in MaxCyte had a market capitalisation of $306.18m.
Here are the trading details for MaxCyte:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MXCT
Based on an overall assessment of its quality, value and momentum MaxCyte is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in MaxCyte is $7.33. That is 154.51% above the last closing price of $2.88.
Analysts covering MaxCyte currently have a consensus Earnings Per Share (EPS) forecast of -$0.36 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MaxCyte. Over the past six months, its share price has underperformed the S&P500 Index by -14.97%.
As of the last closing price of $2.88, shares in MaxCyte were trading -25.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MaxCyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
MaxCyte's management team is headed by:
- Richard Douglas - NEC
- Douglas Doerfler - PRE
- Amanda Murphy - CFO
- Maher Masoud - EVP
- Thomas Ross - EVP
- Ronald Holtz - SVP
- James Brady - VPR
- Kevin Gutshall - VPR
- Steve Nardi - VPR
- Kathryn Wekselman - VPR
- Sarah Meeks - VBD
- Yasir Al-Wakeel - NED
- Rekha Hemrajani - NED
- William Brooke - NID
- Stanley Erck - NID
- John Johnston - NID
- Arthur Mandell - NID